The FDA has accepted Danziten, a brand new formulation of nilotinib, for adults with newly recognized or resistant Philadelphia chromosome-positive continual myeloid leukemia...
The mixture of anti-TIGIT antibody vibostolimab, Keytruda and chemotherapy didn't enhance total survival in contrast with Tecentriq and chemotherapy in sufferers with extensive-stage...
The FDA accredited Revuforj (revumenib) for adults and youngsters with relapsed or refractory acute leukemia with a KMT2A translocation.The Meals and Drug Administration...
